Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21

References

• Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer. Lancet. 2014;384(9951):1376–1388.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391(10125):1023–1075.
   PubMed Web of Science ®Google Scholar
• Zhao M, Qiu Y, Yang B, et al. Long non-coding RNAs involved in gynecological cancer. Int J Gynecol Cancer. 2014;24(7):1140–1145.
   PubMed Web of Science ®Google Scholar
• Medrzycki M, Zhang Y, Zhang W, et al. Histone h1.3 suppresses h19 noncoding RNA expression and cell growth of ovarian cancer cells. Cancer Res. 2014;74(22):6463–6473.
   PubMed Web of Science ®Google Scholar
• Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med. 2016;44(11):2079–2103.
   PubMed Web of Science ®Google Scholar
• Melloni C, Devivo P, Launo C, et al. Cisatracurium versus vecuronium: a comparative, double blind, randomized, multicenter study in adult patients under propofol/fentanyl/N2O anesthesia. Minerva Anestesiol. 2006;72(5):299–308.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Albrecht S, Petterich N, et al. Priming technique with cisatracurium Onset time at the laryngeal muscles. Anaesthesist. 2007;56(10):992–1000.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Lien CA, Belmont MR, et al. Edrophonium effectively antagonizes neuromuscular block at the laryngeal adductors induced by rapacuronium, rocuronium and cisatracurium, but not mivacurium. Can J Anaesth. 2003;50(9):879–885.
   PubMed Web of Science ®Google Scholar
• Lv W, Wang J, Zhang S. Effects of cisatracurium on epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma. Oncol Lett. 2019;18(5):5325–5331.
   PubMed Web of Science ®Google Scholar
• Jiang A, Zhao H, Liu X, et al. Comparison of different muscle-relaxant anesthetics on growth, migration and invasion of gastric cancer cells. Anticancer Res. 2017;37(8):4371–4378.
   PubMed Web of Science ®Google Scholar
• Yabasin IB, Sanches JGP, Ibrahim MM, et al. Cisatracurium retards cell migration and invasion upon upregulation of p53 and inhibits the aggressiveness of colorectal cancer. Front Physiol. 2018;9:941.
   PubMed Web of Science ®Google Scholar
• Yabasin IB, Lu Z, Yu JC, et al. Cisatracurium-induced proliferation impairment and death of colorectal cancer cells, HCT116 is mediated by p53 dependent intrinsic apoptotic pathway in vitro. Biomed Pharmacother. 2017;91:320–329.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Riscal R, Arena G, et al. Metabolic functions of the tumor suppressor p53: implications in normal physiology, metabolic disorders, and cancer. Mol Metab. 2020;33:2–22.
   PubMed Web of Science ®Google Scholar
• Miyajima C, Kawarada Y, Inoue Y, et al. Transcriptional coactivator TAZ negatively regulates tumor suppressor p53 activity and cellular senescence. Cells. 2020;9(1):171.
   PubMed Web of Science ®Google Scholar
• Dinarvand N, Khanahmad H, Hakimian SM, et al. Expression and clinicopathological significance of lipin-1 in human breast cancer and its association with p53 tumor suppressor gene. J Cell Physiol. 2020;235(7–8):5835–5846.
   PubMed Web of Science ®Google Scholar
• Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. Cell. 2010;142(3):409–419.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Miao Y, Shang M, et al. LincRNA-p21 leads to G1 arrest by p53 pathway in esophageal squamous cell carcinoma. Cancer Manag Res. 2019;11:6201–6214.
   PubMedGoogle Scholar
• Wang G, Li Z, Zhao Q, et al. LincRNA-p21 enhances the sensitivity of radiotherapy for human colorectal cancer by targeting the Wnt/β-catenin signaling pathway. Oncol Rep. 2014;31(4):1839–1845.
   PubMed Web of Science ®Google Scholar
• Wang T, Liu J, Li S, et al. Effects of knockout of lincRNA-p21 on the proliferation, migration and invasion ability of HepG2 liver cancer cells. Oncol Lett. 2019;17(6):5103–5107.
   PubMed Web of Science ®Google Scholar
• Yu F, Lu Z, Chen B, et al. Identification of a novel lincRNA-p21-miR-181b-PTEN signaling cascade in liver fibrosis. Mediators Inflamm. 2016;2016:9856538.
   PubMed Web of Science ®Google Scholar
• Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014;447(3):446–451.
   PubMed Web of Science ®Google Scholar
• Sandra K, Krombach JW, Christoph D. Muscle relaxants. Best Pract Res Clin Anaesthesiol. 2019;17(1):137–146.
   Google Scholar
• Plaud B, Baillard C, Bourgain JL, et al. Guidelines on muscle relaxants and reversal in anaesthesia. Anaesth Crit Care Pain Med. 2020;39(1):125–142.
   PubMed Web of Science ®Google Scholar
• Yabasin I, Ibrahim M, Adam A, et al. Anticancer effects of vecuronium bromide and cisatracurium besylate on lung cancer cells (A549), in vitro. Biomed Aging Pathol. 2014;4(4):349–353. .
   Google Scholar
• Lane Dp F, Crawford LV, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278(5701):261–263.
   PubMed Web of Science ®Google Scholar
• Fuster JJ, Sanz-González SM, Moll UM, et al. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med. 2007;13(5):192–199.
   PubMed Web of Science ®Google Scholar
• Shi C, Yu L, Yang F, et al. A novel organoselenium compound induces cell cycle arrest and apoptosis in prostate cancer cell lines. Biochem Biophys Res Commun. 2003;309(3):578–583.
   PubMed Web of Science ®Google Scholar
• Harvey M, McArthur MJ, Montgomery CA, et al. Genetic background alters the spectrum of tumors that develop in p53-deficient mice. Faseb J. 1993;7(10):938–943.
   PubMed Web of Science ®Google Scholar
• Jin S, Yang X, Li J, et al. p53-targeted lincRNA-p21 acts as a tumor suppressor by inhibiting JAK2/STAT3 signaling pathways in head and neck squamous cell carcinoma. Mol Cancer. 2019;18(1):38.
   PubMedGoogle Scholar
• Yang N, Fu Y, Zhang H, et al. LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma. Oncotarget. 2015;6(29):28151–28163.
   PubMedGoogle Scholar
• Chen Y, Wei G, Xia H, et al. Down regulation of lincRNA-p21 contributes to gastric cancer development through Hippo-independent activation of YAP. Oncotarget. 2017;8(38):63813–63824.
   PubMedGoogle Scholar
• Wang X, Xu Y, Wang X, et al. LincRNA-p21 suppresses development of human prostate cancer through inhibition of PKM2. Cell Prolif. 2017;50(6):e12395.
   Web of Science ®Google Scholar
• Yoon JH, Abdelmohsen K, Srikantan S, et al. LincRNA-p21 suppresses target mRNA translation. Mol Cell. 2012;47(4):648–655.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203–222.
   PubMed Web of Science ®Google Scholar
• Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol. 2010;22(1):35–45.
   PubMed Web of Science ®Google Scholar
• Pan X, Feng J, Zhu Z, et al. A positive feedback loop between miR-181b and STAT3 that affects Warburg effect in colon cancer via regulating PIAS3 expression. J Cell Mol Med. 2018;22(10):5040–5049.
   PubMed Web of Science ®Google Scholar
• Li X, Han J, Zhu H, et al. miR‑181b‑5p mediates TGF‑β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells. Int J Oncol. 2017;51(1):158–168.
   PubMed Web of Science ®Google Scholar
• Tian F, Shen Y, Chen Z, et al. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer. Gene. 2016;591(2):338–343.
   PubMed Web of Science ®Google Scholar